Zobrazeno 1 - 10
of 77
pro vyhledávání: '"shorter regimen"'
Autor:
Daniel Legese Achalu, Adamu Bayissa Kiltu, Mekonnen Teferi, Foziya Getachew Mohammed, Birhanu Demeke Workneh, Kebede Abera Beyene, Gebremedhin Beedemariam Gebretekle, Eskinder Eshetu Ali
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The injectable shorter multi-drug resistant tuberculosis (MDR-TB) regimen, has been reported to be less costly and more effective in the treatment of MDR-TB compared to the longer regimen. Ethiopia introduced the injectable shorte
Externí odkaz:
https://doaj.org/article/c2d7e1d08cbf454a90588c47b8537dde
Autor:
Laura Rosu, Jason Madan, Gay Bronson, Jasper Nidoi, Mamo G. Tefera, Muniyandi Malaisamy, Bertel S. Squire, Eve Worrall
Publikováno v:
BMC Health Services Research, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background In 2017, the WHO recommended the use of digital technologies, such as medication monitors and video observed treatment (VOT), for directly observed treatment (DOT) of drug-susceptible TB. The WHO’s 2020 guidelines extended these
Externí odkaz:
https://doaj.org/article/96f49bb240254164966b2fa092da58d3
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 19, Pp 889-901 (2023)
Daniel Legese Achalu,1 Foziya Getachew Mohammed,2 Mekonnen Teferi1 1Clinical Trial Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia; 2Knowledge Management Directorate, Armauer Hansen Research Institute, Addis Ababa, EthiopiaCorre
Externí odkaz:
https://doaj.org/article/825a634806924562a2db49242d2a3ef1
Publikováno v:
Journal of Family Medicine and Primary Care, Vol 12, Iss 6, Pp 1087-1091 (2023)
Background: According to Indian TB report 2020, 66,225 MDR/RR-TB cases were detected in India, 56,569 (85%) were put on treatment, and 40,397 (75%) were initiated on shorter drug regimens at the time of diagnosis. In the absence of an effective vacci
Externí odkaz:
https://doaj.org/article/c1150e5a2df34b82bdc40785b7f3da84
Autor:
Thi Mai Phuong Nguyen, Thi Hai Minh Le, Corinne Simone Collette Merle, Debora Pedrazzoli, Nhat Linh Nguyen, Tom Decroo, Binh Hoa Nguyen, Thi Thanh Thuy Hoang, Viet Nhung Nguyen
Publikováno v:
International Journal of Infectious Diseases, Vol 126, Iss , Pp 148-154 (2023)
ABSTRACT: Objectives: World Health Organization recommends a 7-drug 9–11-month rifampicin-resistant tuberculosis (RR-TB) short treatment regimen (STR). To reduce the pill burden, we assessed the safety and effectiveness of a 5-drug 9–11-month mod
Externí odkaz:
https://doaj.org/article/bf5714077648417bb949205cd923c525
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nakwon Kwak, Doosoo Jeon, Youngmok Park, Young Ae Kang, Kyung Jong Kim, Young Ran Kim, Byoung Soo Kwon, Yong-Soo Kwon, Hyung-Jun Kim, Jae Ho Lee, Ji Yeon Lee, Jung-Kyu Lee, Jeongha Mok, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background The standard treatment regimen for drug-sensitive tuberculosis (TB), comprising four companion drugs, requires a minimum duration of 6 months, and this lengthy treatment leads to poor adherence and increased toxicity. To improve r
Externí odkaz:
https://doaj.org/article/eb945c4ec1694f4fb6e83e604aea77a8
Autor:
Elisa Vanino, Bianca Granozzi, Onno W. Akkerman, Marcela Munoz-Torrico, Fabrizio Palmieri, Barbara Seaworth, Simon Tiberi, Marina Tadolini
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp S12-S15 (2023)
In December 2022 World Health Organization released a new treatment for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main novelty of this update is two new recommendations (i) a 6-month treatment regimen composed o
Externí odkaz:
https://doaj.org/article/08c76aff61794afa9b172b861ebc87f4
Publikováno v:
International Journal of Mycobacteriology, Vol 11, Iss 3, Pp 261-267 (2022)
Background: The drug regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) has lower potency, is more costly, and has a greater risk of adverse effects than first-line anti-TB drugs. We aimed to compare the treatment outcomes of pati
Externí odkaz:
https://doaj.org/article/bebcf70735104c8ab4e1df159fb53499
Autor:
Kiran B, Rupak Singla, Neeta Singla, Vinay V, Kuljeet Singh, Madhumita Paul Choudhury, Nilotpal Bhattacherjee
Publikováno v:
Monaldi Archives for Chest Disease (2022)
Rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) is a significant burden on global tuberculosis (TB) prevention and eradication efforts. MDR-TB can be treated, but it is expensive, takes a long time (typically two years), and contain
Externí odkaz:
https://doaj.org/article/49e5e7c7bab6411397606d6c23859d31